in an attempt to evaluate the long-term immunogenicity and efficacy of plasma-derived hepatitis b vaccine in preventing hepatitis b virus infection , 199 infants born to hepatitis b e antigen-positive hepatitis b surface antigen-carrier mothers were found to be antibody to hbsag-positive ( greater than or equal to 10 miu per ml ) 2 months after the first booster of hepatitis b vaccination at age 1 , and their serum hbsag and anti-hbs were rechecked annually to ages 3 to 5 .
C0032105
plasma
C0229671
serum